This website is intended for healthcare professionals only.
Take a look at a selection of our recent media coverage:
18th April 2022
Bipolar disorder is associated with an increased risk of developing osteoporosis but this risk is lower among patients treated with lithium but not any of the other anti-psychotics. This was the finding of a retrospective analysis by a team from the Psychosis Research Unit, Aarhus University Hospital, Aarhus, Denmark.
Bipolar disorder (BD) is best described as a multicomponent illness involving episodes of severe mood disturbance, neuropsychological deficits, immunological and physiological changes, and disturbances in functioning.
According to the World Health Organization, BD affects about 45 million people worldwide. Osteoporosis is a disease of the bones and characterised by a reduction in bone mineral density and a decrease in bone mass or when the quality or structure of bone changes.
Having osteoporosis increases an individual’s risk of fractures and while there are several factors associated with an increased risk for developing the condition, one purported factor is bipolar disorder, though to date, the evidence is far from conclusive but suggestive. For example, one study identified how patients with BD had a lower bone mineral density (a risk factor for osteoporosis) when compared to an age and gender matched healthy control sample.
In addition, other studies have shown that BD is associated with an increased fracture risk. Lithium is an effective mood stabiliser that is used principally for the management of bipolar disorder and there is some evidence points to the fact that lithium use is associated with a significant decreased risk of fracture.
In an attempt to better comprehend both the relationship between BD and osteoporosis and the impact of lithium therapy, the Danish team turned to a national, longitudinal register. They first sought to compare the incidence of osteoporosis among those with BD in comparison to the general population and secondly, whether the usual treatments for BD including lithium and other anti-psychotics were protective. The primary outcome measure was osteoporosis and this was determined from both hospital diagnoses and prescribed treatments.
Bipolar disorder and osteoporosis risk
A total of 22,912 individuals with BD and a median age of 50.4 years (56.6% women) and 114,560 reference individuals (without BD) were followed over a median of 7.68 years. Among those with BD, 38.2% were prescribed lithium, 73.6% an anti-psychotic, 16.8% valproate and 33.1% lamotrigine.
During this follow-up period, patients with BD had a 14% higher risk of developing osteoporosis compared to the reference group (hazard ratio, HR = 1.14, 95% CI 1.08 – 1.20).
However, when the researchers compared those prescribed lithium to no lithium, there was a substantial decreased risk of developing osteoporosis in fully adjusted models (HR = 0.62, 95% CI 0.53 – 0.72. In contrast, there was no such significant associations for any of the other prescribed treatments.
The authors concluded that patients with BD have an elevated risk of osteoporosis and that treatment with lithium reduces this risk, suggesting that bone health should become a priority in the clinical management of these patients.
Köhler-Forsberg O et al. Association of Lithium Treatment With the Risk of Osteoporosis in Patients With Bipolar Disorder JAMA Psychiatry 2022